Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
about
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@en
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@nl
type
label
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@en
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@nl
prefLabel
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@en
Glyco-engineered Long Acting F ...... e Monthly Subcutaneous Dosing.
@nl
P2093
P2860
P1433
P1476
Glyco-engineered Long Acting F ...... ce Monthly Subcutaneous Dosing
@en
P2093
Alison Joyce
Alison Logan
Annette Sievers
Barbara Bernardo
Craig Giragossian
Darwin Lee
Denise M O'Hara
Dongmei Li
Eric Sousa
P2860
P356
10.1038/S41598-018-22456-W
P407
P577
2018-03-09T00:00:00Z